Pay in 4 interest-free payments of $7.16 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has demonstrated efficacy in aiding weight loss, but it may also pose certain risks to individuals undergoing treatment
In addition to its glucose-lowering and weight-loss effects, tirzepatide is currently undergoing Phase 3 or 4 clinical trials for other conditions, including obesity with osteoarthritis, atherosclerosis in T2DM patients, lipid metabolism and brain function in T2DM patients, and obstructive sleep apnea
Flushing and Vascular Stress Both peptides can cause flushing and changes in circulation, creating discomfort or placing added stress on the vascular system
Statistical significance was assessed using a two-sided t-test with permutation-based false discovery rate (FDR) correction (1%)
US$ 21.23
US$ 23.16
US$ 25.29
